Brain Metastases and Radiation: The Core Choice
When cancer spreads to the brain from another organ, it is called a brain metastasis — or brain metastases when multiple deposits are present. This differs from a primary brain tumor like glioblastoma. Yet radiation therapy plays a central role in treating both. For brain metastases specifically, the radiation decision most often comes down to two main approaches: stereotactic radiosurgery (SRS) and whole brain radiation therapy (WBRT).
These two approaches work differently and suit different clinical situations. Understanding the distinction helps patients and families ask better questions of their care teams and take a more active role in treatment decisions.
According to the American Brain Tumor Association, metastatic brain tumors are the most common brain tumors in adults, affecting roughly 10 to 30 percent of people with cancer. About 200,000 new cases are diagnosed in the United States each year.
What Is Stereotactic Radiosurgery?
Despite its name, SRS does not involve a scalpel. No incisions are made. Instead, it uses precisely focused, image-guided radiation beams to deliver a high dose directly to one or more tumor sites. The surrounding brain tissue receives a far lower dose, which is the key advantage.
Common delivery platforms include the Gamma Knife, CyberKnife, and linear accelerator (LINAC)-based systems. All use detailed MRI or CT imaging to map each lesion in three dimensions before treatment begins. The precision of the dose allows clinicians to treat a tumor while sparing the memory centers and other critical structures nearby.
Most SRS courses take one to five sessions. When multiple sessions are used, the approach is called fractionated SRS or stereotactic radiotherapy (SRT). Doctors often prefer fractionation for larger lesions — generally those over 2 to 3 centimeters in diameter — where delivering the full dose in a single session carries a higher risk of radiation necrosis or other complications.
SRS works best when lesions are distinct and clearly visible on imaging. It cannot reliably treat microscopic deposits that imaging has not yet detected, which is one reason WBRT has historically remained an option for patients with many lesions or certain tumor types.
What Is Whole Brain Radiation Therapy?
WBRT treats the entire brain — including visible tumors and the surrounding tissue where microscopic cancer cells may hide but imaging cannot yet detect. Doctors deliver radiation in smaller daily fractions, typically over two to three weeks, for a total of ten to fifteen sessions.
The logic is broad coverage. When metastases are numerous, too small to target individually, or located in areas where focal radiation is difficult to deliver, whole brain treatment covers both visible and occult disease.
WBRT dominated the treatment of brain metastases for decades. Its role has narrowed considerably as SRS technology improved and research revealed the cognitive cost of whole brain irradiation.
What the Clinical Evidence Shows
The clearest finding from clinical research involves cognitive outcomes. A major randomized trial published in JAMA compared SRS alone versus SRS combined with WBRT in patients with one to three brain metastases. Patients who received SRS alone had significantly less cognitive deterioration at three months. That trial found that adding WBRT to SRS increased cognitive harm without improving survival — a finding that shifted practice toward SRS-first approaches for limited disease.
Research on cognition-preservation strategies in brain metastases patients, available on PubMed Central, confirms that WBRT damages memory and processing speed by harming the hippocampus — the brain region most critical for forming new memories. These cognitive effects can appear weeks to months after treatment and often last long-term.
On survival, SRS and WBRT show comparable results for patients with limited brain metastases. The real difference is in quality of life, not survival statistics. This trade-off has led major guideline bodies to recommend SRS as the preferred approach for patients with a limited number of metastases and adequate performance status.
In 2022, a joint guideline from ASCO, the Society for Neuro-Oncology (SNO), and ASTRO recommended offering SRS alone — rather than adding WBRT — to patients with one to four unresected brain metastases and good performance status. Small-cell lung cancer is a notable exception, as its biology and evidence base differ from most solid tumors.
More recently, the CYBER-SPACE randomized phase II trial studied SRS for one to ten brain metastases as an alternative to WBRT. This adds to evidence that SRS may work beyond the traditional four-lesion threshold in selected patients.
Factors That Favor SRS
Several clinical features make SRS the better choice in a given case:
- Limited number of lesions. One to four discrete metastases represent the clearest indication for SRS alone. Doctors are treating more lesions with SRS, but guidance varies by institution and case complexity.
- Smaller lesion size. Lesions under approximately 3 centimeters in diameter typically respond well to single-session SRS. Larger lesions may need fractionated SRS, surgical resection, or a combined approach.
- Priority on cognitive preservation. Patients who value protecting memory and thinking — especially those expected to live longer — have the most to gain from avoiding WBRT. The cognitive harm from WBRT matters most when a patient is expected to live long enough to experience it.
- Good performance status. Functionally active patients benefit most from the lower toxicity profile of SRS. Patients already significantly impaired from systemic disease may tolerate either approach similarly.
- Active systemic therapy. When immunotherapy or targeted drugs are controlling the primary cancer, keeping brain treatment focal lets systemic therapy continue with fewer interruptions and less combined toxicity.
Factors That Favor WBRT
Despite the trend toward SRS, WBRT remains appropriate in certain situations:
- Numerous or diffuse lesions. When many metastases scatter throughout the brain — particularly when targeting each one is technically complex or impractical — WBRT offers broader coverage more efficiently.
- Leptomeningeal involvement. When cancer spreads to the fluid-filled spaces around the brain and spinal cord, SRS alone is usually insufficient. WBRT can irradiate the entire cranial compartment, though outcomes for leptomeningeal disease remain difficult.
- Small-cell lung cancer. SCLC tends to spread to the brain diffusely. Current guidelines continue to support WBRT in certain SCLC scenarios — including prophylactic cranial irradiation in limited-stage disease — based on its specific evidence.
- Palliative intent with limited prognosis. For patients with significant systemic disease and pressing neurological symptoms, WBRT can deliver relief through a relatively short two- to three-week course.
- Post-surgical scenarios involving multiple resected sites. In rare complex cases involving several surgically treated lesions, doctors may discuss WBRT — though SRS to the resection cavity has become the preferred approach for most patients after single or limited resections.
Hippocampal-Avoidant WBRT and Memantine: Reducing the Cognitive Cost
For patients who need WBRT, newer techniques can reduce — though not eliminate — its cognitive impact. Hippocampal-avoidant WBRT (HA-WBRT) uses intensity-modulated radiation planning to spare the hippocampus while treating the rest of the brain. Clinical studies show HA-WBRT reduces memory decline compared with standard WBRT. It is not appropriate for patients with metastases near the hippocampus, since sparing that region would leave tumor untreated. For patients without hippocampal involvement, it works better than standard WBRT.
Memantine — an NMDA receptor antagonist used in Alzheimer's disease — has also been studied alongside WBRT. A randomized trial found that patients taking memantine during and after WBRT showed better preservation of cognitive function over time compared to those receiving placebo. The ASCO-SNO-ASTRO guideline recommends offering both HA-WBRT and memantine to eligible patients who require whole brain radiation and have four or more months of expected survival.
If WBRT is being recommended, ask specifically about both of these modifications. This is an important part of deciding about your treatment.
Radiation Necrosis: A Known Risk With SRS
Radiation necrosis occurs when radiation damages brain tissue. This damage comes from treatment, not from tumor regrowth. It can develop months to years after treatment and looks identical to tumor progression on standard MRI, making diagnosis difficult.
SRS carries a known risk of radiation necrosis, particularly for larger lesions or when a previously radiated area is re-treated. The risk is limited to the treated site, but necrosis can cause neurological symptoms that need evaluation and sometimes treatment with corticosteroids, bevacizumab, or surgical intervention.
When new enhancement appears on a follow-up MRI after SRS, your team will likely recommend advanced imaging — such as perfusion MRI, MR spectroscopy, or amino acid PET — to tell necrosis from true recurrence. The article on radiation necrosis versus tumor recurrence explains how doctors make this distinction and what treatment options exist.
Scalp and Hair: Practical Side Effects of Brain Radiation
Both SRS and WBRT can cause scalp irritation and temporary hair loss, though the pattern differs. WBRT tends to produce more diffuse scalp effects because it treats the entire cranial field. SRS may cause focal thinning or loss over the treated area with less overall scalp involvement.
Hair loss from brain radiation is usually temporary, with regrowth starting within a few months of finishing treatment. Texture or density can change. Managing scalp skin during and after radiation is a practical concern that deserves attention alongside larger treatment decisions. The article on managing scalp irritation and hair loss during brain radiation addresses these effects in detail.
Monitoring After Treatment
After SRS or WBRT, regular MRI is the standard way to monitor tumor response and detect new lesions. Most radiation oncologists recommend brain MRI every two to three months for the first year following treatment. New metastases can appear after successful treatment of initial lesions — driven by ongoing systemic disease or circulating tumor cells that were too small to detect at the time of first treatment.
Patients who had SRS for a limited number of lesions may need repeat SRS for newly appearing metastases. This salvage SRS approach is well-established and safe in appropriately selected patients. It often lets doctors spare patients from WBRT altogether.
For families supporting a loved one with brain metastases through treatment, the caregiver guide for brain metastases offers a practical overview of what to expect — from initial diagnosis through follow-up and potential retreatment.
Questions to Bring to Your Radiation Oncologist
When meeting with your radiation oncology team, these questions can help structure the conversation:
- How many lesions are visible on my current MRI, and are all of them targetable with SRS?
- What is the estimated risk of new lesions developing over the next six to twelve months given my primary cancer status?
- If I start with SRS, could I still receive WBRT later if needed?
- Am I a candidate for hippocampal-avoidant WBRT and memantine if WBRT is recommended?
- How does my systemic therapy interact with radiation timing and selection?
- Are there open clinical trials studying radiation approaches for my tumor type and metastasis pattern?
When to Talk to Your Doctor
Contact your oncologist or radiation oncologist right away if you develop new or worsening neurological symptoms between scheduled appointments — including headaches, balance problems, vision changes, weakness on one side of the body, or sudden confusion. These may signal new metastases, treatment-related swelling, or radiation necrosis that needs evaluation before your next scheduled scan.
Ask your care team explicitly: what symptoms should prompt an unscheduled call, and who is the right contact person in those moments? Getting clear guidance on this before treatment begins reduces delays when something changes.
This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.